Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 7 - Drugs for disorders of the blood or the extracellular fluid
Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
03/2005
03/31/2005US20050069876 Polypeptide for use in diagnosis, treatment and prevention of cell proliferative, autoimmune, inflammatory, cardiovascular, neurological and developmental disorders.
03/31/2005US20050069577 Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies
03/31/2005US20050069559 Lawsonia intracellularis vaccine
03/31/2005US20050069547 Binding protein; therapy for bone tumors
03/31/2005US20050069533 Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and products thereof
03/31/2005US20050069276 Deuterated pyrazolopyrimidinones and drugs containing said compounds
03/31/2005CA2539301A1 Abiotic heparin antagonists
03/31/2005CA2538366A1 Concurrent drugs
03/30/2005EP1518931A1 Use of P-selectin glycoprotein ligand-1 (PSGL-1) and fragments thereof for the inhibition of thrombosis
03/30/2005EP1518864A2 Antibody against rhesus D
03/30/2005EP1518556A1 Therapeutic agent for brain hemorrhage
03/30/2005EP1517924A1 Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained
03/30/2005EP1517919A2 Marked peptides having affinity for a phospholipid and uses
03/30/2005EP1517918A2 Peptides having affinity for a phospholipid and uses
03/30/2005EP1517897A2 Benzimidazole compounds and their use as estrogen agonists/antagonists
03/30/2005EP1517710A1 Pegylated factor vii glycoforms
03/30/2005EP1517698A1 Stabilised solid compositions of factor vii polypeptides
03/30/2005EP1517685A1 2-(phenyl)-2h-pyrazole-3-carboxylic acid-n-4-(thioxo-heterocyclyl)-phenyl-amide derivatives and corresponding imino-heterocyclyl derivatives and relates compounds for use as inhibitors of the coagulation factors xa and/or viia for treating thromboses
03/30/2005EP1517681A1 Peritoneal dialysate containing taurine
03/30/2005EP1322350B1 E-ptfe foil impregnated with an encapsulated bioactive substance
03/30/2005EP1250092B1 Method for preventing fluorescence quenching
03/30/2005EP1242089B1 Use of adatanserin for the treatment of acute neurodegenerative disorders
03/30/2005EP1224298B1 Fibrinolytically active polypeptide
03/30/2005EP1200105B1 Modified factor viii
03/30/2005EP1194140B1 Pharmaceutical composition containing fenofibrate and preparation method
03/30/2005EP1135414B1 Allo and auto-reactive t-cell epitopes
03/30/2005CN1602360A Methods of increasing endogenous erythropoietin (EPO)
03/30/2005CN1602354A Human coagulation factor VII polypeptides
03/30/2005CN1602201A Peptides and related compounds having thrombopoietic activity
03/30/2005CN1602187A Valdecoxib-based composition prepared by spray drying process and exhibiting rapid oral dissolution
03/30/2005CN1600362A Combination of medication for curing bleeding
03/30/2005CN1600360A Soft capsule of decoction of four ingredients possessing effect of enriching blood and regulating menstruation and preparation method
03/30/2005CN1600335A Oral taking drug for treating bleeding from internal hemorrhoid and preparation method
03/30/2005CN1600321A Capsule of ass-skin glue and preparation method
03/30/2005CN1600320A Instant agent of donkey-hide gelatin and preparation method
03/30/2005CN1195055C Method for establishing hematopoietic stem cells bank by extracting hematopoietic cells from placenta tissues
03/30/2005CN1194978C Phosphinous and phosphonic acid derivs. used as medicaments
03/30/2005CN1194749C Medicine for treating functional metrorrhagia and preparing process thereof
03/30/2005CN1194711C Instant powder for preventing and treating nutritional iron deficiency anemia
03/30/2005CN1194708C Process for preparing staltic medicine from Taiwan Beautyberry leaf
03/30/2005CN1194701C Application of icaritin or demethylicaritin in preparing estrogen receptor moderator
03/29/2005US6872808 Nematode-extracted serine protease inhibitors and anticoagulant proteins
03/29/2005US6872751 Composition and method for augmenting or restoring the production of fetal protein in patient in need thereof
03/29/2005US6872743 Antiinflammatory agents; sepsis shock; antiarthritic agents
03/29/2005US6872733 Benzimidazolone compounds
03/29/2005US6872730 Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
03/29/2005US6872719 Antiinflammatory agents; autoimmune disease
03/29/2005US6872711 β-substituted β-aminoethyl phosphonate derivatives
03/29/2005US6872409 For inhibiting platelet aggregation, for prolonging bleeding time
03/29/2005US6872391 Nucleotide sequences coding polypeptide for use in the treatment of eating disorders
03/29/2005CA2301732C Therapeutic combinations
03/29/2005CA2170772C Use of nitric oxide-adducts to prevent thrombosis on artificial and vascular surfaces
03/24/2005WO2005026198A1 Base-substituted benzylamine analogs for use as coagulation factor xa inhibitors, the production and use thereof
03/24/2005WO2005026174A1 Novel crystalline polymorphs of clopidogrel
03/24/2005WO2005026127A1 Plasminogen activator inhibitor-1 inhibitor
03/24/2005WO2005025548A1 Topical preparations comprising a hydrophilic carrier and a silicone matrix
03/24/2005WO2005003138A3 Process for the preparation of amorphous form of a platelet aggregation inhibitor drug
03/24/2005WO2005000336A3 The use of caldag-gefi inhibitors as antithrombotic agents
03/24/2005WO2004082702A8 Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy
03/24/2005WO2004063212A3 Organic compounds with biological action as thrombin inhibitors and use therof
03/24/2005WO2004016607A8 Inhibition of phosphoinositide 3-kinase beta
03/24/2005WO2002092759A9 Molecules for disease detection and treatment
03/24/2005US20050065346 anticoagulants; thrombosis; factor x inhibitor
03/24/2005US20050065195 Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors
03/24/2005US20050065163 Platelet adenosine diphosphate receptor antagonists
03/24/2005US20050065148 Dipeptidyl peptidase inhibitors
03/24/2005US20050065093 Inhibitors of the ICE/ced-3 family of cysteine proteases
03/24/2005US20050065084 polynucleotide codes for saratin polypeptides from saliva of leeches, used as antagonist for collagen-dependent platelet adhesion; genetic engineering; prophylaxis of cardiovascular disorders
03/24/2005US20050065067 tetramer-free, substantially stroma-free, polymerized, pyridoxylated hemoglobin; free of leukocytes (white blood cells) and platelets
03/24/2005US20050064458 Nucleotide sequences coding membrane protein for use in diagnosis, prevention and treatnment of cell proliferative, nervous system, metabolic and inflammatory disorders
03/24/2005US20050064404 Regulation of human serotonin-like g protein-coupled receptor
03/24/2005US20050064006 Stents
03/24/2005US20050063971 Monoclonal or humanized antibodies that immunospecifically bind to FGF-CX or any derivative, variant, mutant, polypeptide fragment, polynucleotide or antibody
03/24/2005US20050063943 Conjugated of hydroxyalkyl starch and an active agent
03/24/2005US20050063905 Administering a RADIONUCLIDE COMPLEXED WITH A CHELATING AGENT SUCH AS MACROCYCLIC AMINOPHOSPHONIC ACID, or tetraazacyclododecanetetramethylenephosphonic acid (DOTMP); polycythemia vera, macroglobulinemia (Waldenstrom syndrome), megakaryocytic myelosis, malignant histiocytosis
03/24/2005DE10339862A1 New crystalline forms of ethyl 3-(N-(2-(4-(hexyloxycarbonylamidino)ph enylaminomethyl)-1-methyl-1H-benzimidazole-5-carbonyl)-N-(2-pyridyl)a mino)propionate methanesulfonate used for post-operative prophylaxis of deep vein thrombosis
03/24/2005CA2810312A1 Novel crystalline polymorphs of clopidogrel
03/24/2005CA2809750A1 Novel crystalline polymorphs of clopidogrel
03/24/2005CA2538895A1 Factor ixa specific antibodies displaying factor viiia like activity
03/24/2005CA2538075A1 Base-substituted benzylamine analogs for use as coagulation factor xa inhibitors, the production and use thereof
03/24/2005CA2537250A1 Topical preparations comprising a hydrophilic carrier and a silicone matrix
03/24/2005CA2536052A1 Novel crystalline compounds
03/23/2005EP1516597A1 Drug eluting stent
03/23/2005EP1516064A2 Methods of using 46828, a human acyl-coa synthetase
03/23/2005EP1515978A1 Sulfur-containing phospholipid derivatives
03/23/2005EP1515947A1 Fluorinated cycloalkyl-derivatised benzoylguanidines and their use as a medicament
03/23/2005EP1515942A1 Carboxamides derivatives
03/23/2005EP1515941A1 2-naphthamide derivatives
03/23/2005EP1515753A1 Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
03/23/2005EP1515731A1 Anti-spasmodic comprising xenon
03/23/2005EP1515725A2 Use of cyclothiocarbamate derivatives in treatment of hormone-related conditions
03/23/2005EP1515716A2 Indole derivatives having anti-angiogenetic activity
03/23/2005EP1343542B1 Carrier with solid fibrinogen and solid thrombin
03/23/2005EP1328268B1 Combination of catechin and quercetin for pharmaceutical or dietary use
03/23/2005EP1311285B1 Liquid pharmaceutical composition containing an erythropoietin derivative
03/23/2005EP1181382B1 Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
03/23/2005EP0723398B1 Superoxide dismutase mimetics
03/23/2005CN1599755A Antibodies against caspase-8, their preparation and use
03/23/2005CN1599747A Isolation of lectins
03/23/2005CN1599745A Crystalline form of a ribofuranosyluronamide derivative; a human adenosine a2a receptor agonist
1 ... 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 ... 671